I'm a value investor who enjoys using classical value ratios to pick my portfolio. Long-term focused on low P/B, P/FCF, Owner Earnings discounting, PEG ratios, the Graham Number and an occasional net-net hunter. I also believe tracking earnings growth versus price appreciation is an essential element to any quality evaluation.I advocate self-indexing primarily using the Dow Jones Industrial Average as my index of choice combined with Joel Greenblatt's Magic Formula. This can help with tax efficiency owning ...

McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. The prescription drug distributor's shares have seen a decrease of 13.15% over the last month, not keeping up with the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21%. The investment community will be paying close attention to the earnings perf ...

In the latest trading session, McKesson (MCK) closed at $479.06, marking a -0.02% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%.Prior to today's trading, shares of the prescription drug distributor had lost 13.93% over the past month. This has lagged the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71% in that time.Analysts and investors alike will be keeping a close eye o ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned -13.9%, compared to the Zacks S&P 500 composite's +1.7% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has lost 2.8%. The key question now is: What could be the stock's future direction?While m ...

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally. After a rapid move lower, shares of McKesson Corporation MCKhave become oversold. They have also reached a price level that may provide support. This is why our team of trading experts has made it our Stock of the Day. The red line on the chart below is called a Bollinger Band. It is two standard deviations below the 20-day moving average. According to statistics and ...

Core Insights - McKesson Corporation is positioned for growth due to its strong Biologics business and positive fiscal Q1 2025 performance, despite facing competition and pricing pressures in the generic pharmaceutical market [1] - Over the past year, McKesson shares have increased by 36.1%, outperforming the industry and the S&P 500 [1] - The company has a market capitalization of $64.64 billion and anticipates a 13.4% growth over the next five years [1] Growth Drivers - The Biologics segment is a key growth area, with recent partnerships enhancing its market position, including exclusive agreements with Sentynl Therapeutics and Geron Corporation [2] - McKesson is actively pursuing acquisitions and divestitures to focus on oncology and biopharma services, including the sale of its Rexall and Well.ca businesses and acquiring a controlling interest in Core Ventures [3][4] Financial Performance - McKesson's fiscal Q1 2025 results were mixed, with earnings exceeding estimates but revenues falling short, driven by strong demand in the U.S. pharmaceutical segment [4] - The company experienced a decline in gross profit and margin, attributed to lower COVID-19-related sales and divestitures in Europe [5] Market Challenges - The Distribution Solutions segment faces significant competition from various wholesalers and logistics companies, limiting pricing negotiation power due to reliance on fewer suppliers [5] - Despite these challenges, McKesson has seen a positive estimate revision trend, with a 1.9% increase in the Zacks Consensus Estimate for earnings per share over the past 90 days [6] Revenue Projections - The Zacks Consensus Estimate for Q2 fiscal 2025 revenues is projected at $89.57 billion, reflecting a 16% increase from the previous year [6]

BCFC Introduction This is a very special article, as I discuss a company I have never covered before. As I have been on Seeking Alpha for almost a decade, that doesn't happen very often. As some readers may know, I check the S&P 500's worst performers every day. I do this for the same reason I always check the clearance shelf in stores. You never know when you'll find a bargain! Earlier this month, the McKesson Corporation (NYSE:MCK) stood out, as it saw its stock price decline from $580 to almost $500. ...

The most recent trading session ended with McKesson (MCK) standing at $518.81, reflecting a +1.49% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.72%, and the technology-dominated Nasdaq saw an increase of 0.65%.Heading into today, shares of the prescription drug distributor had lost 6.28% over the past month, lagging the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% in that time.Investors will ...

The most recent trading session ended with McKesson (MCK) standing at $511.17, reflecting a +0.14% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.75% gain on the day. Elsewhere, the Dow saw an upswing of 0.58%, while the tech-heavy Nasdaq appreciated by 1%.The prescription drug distributor's shares have seen a decrease of 7.67% over the last month, not keeping up with the Medical sector's gain of 3.55% and the S&P 500's gain of 4.03%.The investment community will be payin ...

McKesson Corporation (MCK) has agreed to sell its Rexall and Well.ca businesses, both based in Canada, to Birch Hill Equity Partners, a Canadian private equity firm. The deal supports McKesson's strategic decision to concentrate on expanding its oncology and biopharma services while maintaining its focus on the Canadian healthcare market through distribution and biopharma. Through this transaction, Rexall and Well.ca will benefit from Birch Hill's commitment to investing in growth and expanding services acr ...